

LIST OF CONTENTS

NUMBER 1

News	1
Editorial	
Communication as important as cure J.F. Smyth	6
Short Communication	
Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study M. Aapro, J. Van Erps, K. MacDonald, P. Soubeyran, M. Muenzberg, M. Turner, H. Warrinnier, T. Albrecht and I. Abraham	8
Current Perspective	
Current perspective – Trastuzumab P.S. Hall and D.A. Cameron	12
Reviews	
A systematic review of the use and validation of health-related quality of life instruments in older cancer patients D. Fitzsimmons, J. Gilbert, F. Howse, T. Young, J.-I. Arrarras, A. Brédart, S. Hawker, S. George, M. Aapro and C.D. Johnson	19
Prognostic molecular markers in cholangiocarcinoma: A systematic review C.D. Briggs, C.P. Neal, C.D. Mann, W.P. Steward, M.M. Manson and D.P. Berry	33
Clinical Oncology	
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer F. Caponigro, D. Lacombe, C. Twelves, J. Bauer, A.-S. Govaerts, S. Marréaud, A. Milano and A. Anthoney	48
Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases C.P. Neal, C.D. Mann, C.D. Sutton, G. Garcea, S.L. Ong, W.P. Steward, A.R. Dennison and D.P. Berry	56
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The 'GISCAD-alternating schedule' study findings M. Mandalà, S. Barni, I. Floriani, L. Isa, G. Fornarini, M. Marangolo, S. Mosconi, D. Corsi, E. Rulli, L. Frontini, E. Cortesi, A. Zaniboni, M. Aglietta and R. Labianca	65
Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: An EU-FP6 supported study of members of the EORTC – PathoBiology Group P.N. Span, A.M. Sieuwerts, J.J.T.M. Heuvel, F. Spyrtos, M.J. Duffy, S. Eppenberger-Castori, S. Vacher, K. O'Brien, E. McKiernan, A. Pierce, V. Vuaroqueaux, J.A. Foekens, F.C.G.J. Sweep and J.W.M. Martens	74
Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study T.M. Michelsen, A.H. Pripp, S. Tonstad, C.G. Tropé and A. Dørum	82
Paediatric Oncology	
Management and outcome of stage 3 neuroblastoma S. Modak, B.H. Kushner, M.P. LaQuaglia, K. Kramer and N.-K.V. Cheung	90

Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with wilms tumour N.C. Daw, D. Gregornik, J. Rodman, N. Marina, J. Wu, L.E. Kun, J.J. Jenkins, V. McPherson, J. Wilimas and D.P. Jones	99
Epidemiology and Cancer Prevention	
Cervical, endometrial and ovarian cancers among immigrants in Sweden: Importance of age at migration and duration of residence O. Beiki, P. Allebeck, T. Nordqvist and T. Moradi	107
The frequency, magnitude and timing of post-diagnosis body weight gain in Dutch breast cancer survivors W.H. Heideman, N.S. Russell, C. Gundy, M.A. Rookus and D.W. Voskuil	119
Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland R. de Gelder, J.-L. Bulliard, C. de Wolf, J. Fracheboud, G. Draisma, D. Schopper and H.J. de Koning	127
Is bowel habit linked to colorectal cancer? – Results from the EPIC-Norfolk study J.Y. Park, P.N. Mitrou, R. Luben, K.-T. Khaw and S.A. Bingham	139
Experimental Oncology	
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma J. Sadones, A. Michotte, P. Veld, C. Chaskis, R. Sciot, J. Menten, E.J.R. Joossens, T. Strauven, L.A. D'Hondt, D. Sartenaer, S.F.E.H. Califice, K. Bierau, C. Svensson, J. De Grève and B. Neyns	146
Neurotrophin reverses paclitaxel-induced neuropathy without affecting anti-tumour efficacy T. Kawashiri, N. Egashira, Y. Itoh, T. Shimazoe, Y. Ikegami, T. Yano, M. Yoshimura and R. Oishi	154
Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours A.V. Kalra and R.B. Campbell	164
A high cannabinoid CB ₁ receptor immunoreactivity is associated with disease severity and outcome in prostate cancer S.C. Chung, P. Hammarsten, A. Josefsson, P. Stattin, T. Granfors, L. Egevad, G. Mancini, B. Lutz, A. Bergh and C.J. Fowler	174
Referees 2008	183
List of Contents, Volume 45, 2009	185
Author Index, Volume 45, 2009	213
Calendar of Forthcoming Meetings	I

NUMBER 2

Response Assessment in Solid Tumours (RECIST):

Version 1.1 and supporting papers

Guest Editors: E. Eisenhauer, J. Verweij and P. Therasse

Cancer clinical trial outcomes: Any progress in tumour-size assessment? J. Verweij, P. Therasse and E. Eisenhauer, on behalf of the RECIST working group	225
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe and J. Verweij	228

Individual patient data analysis to assess modifications to the RECIST criteria <i>J. Bogaerts, R. Ford, D. Sargent, L.H. Schwartz, L. Rubinstein, D. Lacombe, E. Eisenhauer, J. Verweij and P. Therasse, for the RECIST Working Party</i>	248
Evaluation of lymph nodes with RECIST 1.1 <i>L.H. Schwartz, J. Bogaerts, R. Ford, L. Shankar, P. Therasse, S. Gwyther and E.A. Eisenhauer</i>	261
Lessons learned from independent central review <i>R. Ford, L. Schwartz, J. Dancey, L.E. Dodd, E.A. Eisenhauer, S. Gwyther, L. Rubinstein, D. Sargent, L. Shankar, P. Therasse and J. Verweij</i>	268
Optimising the design of phase II oncology trials: The importance of randomisation <i>M.J. Ratain and D.J. Sargent</i>	275
Recommendations for the assessment of progression in randomised cancer treatment trials <i>J.E. Dancey, L.E. Dodd, R. Ford, R. Kaplan, M. Mooney, L. Rubinstein, L.H. Schwartz, L. Shankar and P. Therasse</i>	281
Validation of novel imaging methodologies for use as cancer clinical trial end-points <i>D.J. Sargent, L. Rubinstein, L. Schwartz, J.E. Dancey, C. Gatsonis, L.E. Dodd and L.K. Shankar</i>	290
A simulation study to evaluate the impact of the number of lesions measured on response assessment <i>C.S. Moskowitz, X. Jia, L.H. Schwartz and M. Gönen</i>	300

NUMBER 3

News	311
Editorial	
Adjuvant 5-FU based chemotherapy for colon cancer: Match or miss the mismatch? <i>M. D'Incalci</i>	316
What to do after winning the Nobel Prize – Work harder! <i>J.F. Smyth</i>	318
Obituary	
In memoriam Professor Lloyd R. Kelland – Man of science <i>H. Newell, M. McKeage and C. Stanway</i>	319
Short communications	
The oncogenic activity of the Src family kinase Hck requires the cooperative action of the plasma membrane- and lysosome-associated isoforms <i>R. Poincloux, T.A. Saati, I. Maridonneau-Parini and V. Le Cabec</i>	321
Adolescents with cancer in Italy: Entry into the national cooperative paediatric oncology group AIEOP trials <i>A. Ferrari, E. Dama, A. Pession, R. Rondelli, C. Pascucci, F. Locatelli, S. Ferrari, M. Mascarin, F. Merletti, G. Masera, M. Aricò and G. Pastore</i>	328
Position paper	
Methylated genes as new cancer biomarkers <i>M.J. Duffy, R. Napieralski, J.W.M. Martens, P.N. Span, F. Spyrtatos, F.C.G.J. Sweep, N. Brunner, J.A. Foekens and M. Schmitt, on behalf of the EORTC PathoBiology Group</i>	335
Reviews	
Patient-reported outcomes: Assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency <i>A. Bottomley, D. Jones and L. Claassens</i>	347

OECI Workshop on late side-effects of cancer treatments R. Arriagada, D. Averbeck, A.A. Dahl, S. Darby, S. Fosså, S. Friberg, C. Polgár and F. de Vathaire	354
Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer J.W. Black	360
Clinical oncology	
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status R. Jover, P. Zapater, A. Castells, X. Llor, M. Andreu, J. Cubiella, F. Balaguer, L. Sempere, R.M. Xicola, L. Bujanda, J.M. Reñé, J. Clofent, X. Bessa, J.D. Morillas, D. Nicolás-Pérez, E. Pons, A. Payá and C. Alenda, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association	365
Communicating cancer diagnosis and prognosis: When the target is the elderly patient-a GIOGer study L. Repetto, P. Piselli, M. Raffaele and C. Locatelli, for the GIOGer	374
A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome S. Alexander, O. Minton, P. Andrews and P. Stone	384
Are Australian oncology health professionals burning out? A view from the trenches A. Girgis, V. Hansen and D. Goldstein	393
Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1–3 brain metastases: Results of a matched pair analysis D. Rades, J.-D. Kueter, T. Veninga, J. Gliemroth and S.E. Schild	400
Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers – Results of a large scale microarray analysis A. Rody, T. Karn, E. Ruckhäberle, L. Hanker, D. Metzler, V. Müller, C. Solbach, A. Ahr, R. Gätje, U. Holtrich and M. Kaufmann	405
Paediatric oncology	
Does aid reach the poor? Experiences of a childhood leukaemia outreach-programme S. Mostert, M.N. Sitaresmi, C.M. Gundy, Sutaryo and A.J.P. Veerman	414
Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990–2002 R.G. Feltbower, R.J.Q. McNally, S.E. Kinsey, I.J. Lewis, S.V. Picton, S.J. Proctor, M. Richards, G. Shenton, R. Skinner, D.P. Stark, J. Vormoor, K.P. Windebank and P.A. McKinney	420
Association between a pro-inflammatory genetic profile and the risk of chronic atrophic gastritis among older adults from Germany L. Gao, M.N. Weck, A. Nieters and H. Brenner	428
Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: A Swedish prospective case-control study A. Brendle, A. Brandt, R. Johansson, K. Enquist, G. Hallmans, K. Hemminki, P. Lenner and A. Försti	435
Experimental oncology	
The expression of the $\Delta Np73\beta$ isoform of p73 leads to tetraploidy E. Marrazzo, S. Marchini, M. Tavecchio, T. Alberio, S. Previdi, E. Erba, V. Rotter and M. Broggin	443
Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells A. Naldini, I. Filippi, C. Ardinghi, A. Silini, R. Giavazzi and F. Carraro	454
Genome-wide expression profile of sporadic gastric cancers with microsatellite instability M. D'Errico, E.d. Rinaldis, M.F. Blasi, V. Viti, M. Falchetti, A. Calcagnile, F. Sera, C. Saieva, L. Ottini, D. Palli, F. Palombo, A. Giuliani and E. Dogliotti	461

Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells E. Napoleone, F. Zurlo, M.C. Latella, C. Amore, A. Di Santo, L. Iacoviello, M.B. Donati and R. Lorenzet	470
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients P. Gutwein, A. Schramme, N. Sinke, M.S. Abdel-Bakky, B. Voss, N. Obermüller, K. Doberstein, M. Koziolk, F. Fritzsche, M. Johannsen, K. Jung, H. Schaidler, P. Altevogt, A. Ludwig, J. Pfeilschifter and G. Kristiansen	478
RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67 Z. Wang, B. Zhang, L. Jiang, X. Zeng, Y. Chen, X. Feng, Y. Guo and Q. Chen	490
Calendar of Forthcoming Meetings	I

NUMBER 4

News	497
Editorial comment	
Quality control in the surgical management of ovarian cancer patients D.P.J. Barton and C. Pomel	502
Short communications	
Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia F.N.J. Frakking, N. Brouwer, M.D. van de Wetering, I.K. Budde, P.F.W. Strengers, A.D. Huitema, I. Laursen, G. Houen, H.N. Caron, K.M. Dolman and T.W. Kuijpers	505
Dietary acrylamide intake and risk of colorectal cancer in a prospective cohort of men S.C. Larsson, A. Åkesson, L. Bergkvist and A. Wolk	513
Reviews	
EORTC-GCG process quality indicators for ovarian cancer surgery L. Verleye, P.B. Ottevanger, W. van der Graaf, N.S. Reed and I. Vergote, on behalf of the Gynaecological Cancer Group (GCG) of the European Organisation for Research and Treatment of Cancer (EORTC)	517
Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? P.E. Lønning	527
The levels of telomere-binding proteins in human tumours and therapeutic implications J.C. Cookson and C.A. Laughton	536
Clinical oncology	
Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer K.M. Field, M.A. Jenkins, M.L. Friedlander, J.M. McKinley, M.A. Price, P. Weideman, L.A. Keogh, S.A. McLachlan, G.J. Lindeman, J.L. Hopper, P.N. Butow and K.A. Phillips	551
Second non-breast primary cancer following adjuvant therapy for early breast cancer: A report from the International Breast Cancer Study Group L. Gianni, S. Gelber, A. Ravaoli, K.N. Price, I. Panzini, M. Fantini, M. Castiglione-Gertsch, O. Pagani, E. Simoncini, R.D. Gelber, A.S. Coates and A. Goldhirsch	561
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients D.M. Kweekel, H. Gelderblom, N.F. Antonini, T. Van der Straaten, J.W.R. Nortier, C.J.A. Punt and H.-J. Guchelaar	572

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial H. Richly, B. Schultheis, I.A. Adamietz, P. Kupsch, M. Grubert, R.A. Hilger, M. Ludwig, E. Brendel, O. Christensen and D. Strumberg	579
Follow-up with ¹⁸ FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: A prospective study J. van Loon, J. Grutters, R. Wanders, L. Boersma, M. Oellers, A.-M. Dingemans, G. Bootsma, W. Geraedts, C. Pitz, J. Simons, S.A. Fatah, G. Snoep, M. Hochstenbag, P. Lambin and D. De Ruyscher	588
The predictive value of interleukin-8 (IL-8) in hospitalised patients with fever and chemotherapy-induced neutropenia Y.H. Tromp, S.M.G.J. Daenen, W.J. Sluiter and E. Vellenga	596
Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis J.P. da Silveira Nogueira Lima, L.V. dos Santos, E.C. Sasse and A.D. Sasse	601
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis G. von Minckwitz, M. Schwenkglenks, T. Skacel, G.H. Lyman, A.L. Pousa, P. Bacon, V. Easton and M.S. Aapro	608
Epidemiology and cancer prevention	
The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population Z. Kleibl, O. Havranek, I. Hlavata, J. Novotny, J. Sevcik, P. Pohlreich and P. Soucek	618
Health care utilisation and characteristics of long-term breast cancer survivors: Nationwide survey in Denmark V. Peuckmann, O. Ekholm, P. Sjögren, N.K. Rasmussen, P. Christiansen, S. Møller and M. Groenvold	625
Vitamin D and skin cancer: A meta-analysis S. Gandini, S. Raimondi, P. Gnagnarella, J.-F. Doré, P. Maisonneuve and A. Testori	634
Age-standardisation of relative survival ratios of cancer patients in a comparison between countries, genders and time periods A. Pokhrel and T. Hakulinen	642
Experimental oncology	
Xanthine oxidoreductase – Clinical significance in colorectal cancer and in vitro expression of the protein in human colon cancer cells N. Linder, E. Martelin, M. Lundin, J. Louhimo, S. Nordling, C. Haglund and J. Lundin	648
Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity V. Carozzi, A. Chiorazzi, A. Canta, N. Oggioni, A. Gilardini, V. Rodriguez-Menendez, F. Avezza, L. Crippa, C. Ceresa, G. Nicolini, M. Bossi and G. Cavaletti	656
Functional role of the KLF6 tumour suppressor gene in gastric cancer J. Sangodkar, J. Shi, A. DiFeo, R. Schwartz, R. Bromberg, A. Choudhri, K. McClinch, R. Hatami, E. Scheer, S. Kremer-Tal, J.A. Martignetti, A. Hui, W.K. Leung, S.L. Friedman and G. Narla	666
Stat3 activation is required for the growth of U87 cell-derived tumours in mice A. Dasgupta, B. Raychaudhuri, T. Haqqi, R. Prayson, E.G. Van Meir, M. Vogelbaum and S.J. Haque	677
Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression G. Kogianni, M.M. Walker, J. Waxman and J. Sturge	685

Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer Y.O. Al-Bazz, J.C.E. Underwood, B.L. Brown and P.R.M. Dobson	694
The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer – A pilot study D. Edler, K. Stenstedt, K. Öhring, M. Hallström, M. Karlgren, M. Ingelman-Sundberg and P. Ragnhammar	705
Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours S. Dalal and S.A. Burchill	713
Calendar of Forthcoming Meetings	I
NUMBER 5	
News	723
Editorial comments	
Phase 0 (zero) clinical trials: More than zero benefit? J.H.M. Schellens	728
Shorter fractionation schedules in breast cancer radiotherapy: Clinical and economic implications M. Mannino and J.R. Yarnold	730
Short communications	
Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma S. Martín-Algarra, E. Espinosa, J. Rubió, J.J.L. López, J.L. Manzano, L.A. Carrión, A. Plazaola, A. Tanovic and L. Paz-Ares	732
Frequency of the mitochondrial DNA 4977bp deletion in oesophageal mucosa during the progression of Barrett's oesophagus B.H.L. Tan, R.J.E. Skipworth, N.A. Stephens, N.M. Wheelhouse, H. Gilmour, A.C. de Beaux, S. Paterson-Brown, K.C.H. Fearon and J.A. Ross	736
Position paper	
Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies S. Kummar, J.H. Doroshow, J.E. Tomaszewski, A.H. Calvert, M. Lobbezoo and G. Giaccone, on behalf of the Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT)	741
Reviews	
Evaluation of data quality in the cancer registry: Principles and methods.Part I: Comparability, validity and timeliness F. Bray and D.M. Parkin	747
Evaluation of data quality in the cancer registry: Principles and methods Part II. Completeness D.M. Parkin and F. Bray	756
EORTC-GU group expert opinion on metastatic renal cell cancer T.M. de Reijke, J. Bellmunt, H. van Poppel, S. Marreud and M. Aapro	765
Clinical oncology	
Delayed diagnosis of breast cancer in women recalled for suspicious screening mammography L.E.M. Duijm, J.H. Groenewoud, H.J. de Koning, J.W. Coebergh, M. van Beek, M.J.H.H. Hooijen and L.V. van de Poll-Franse	774
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group G. Goss, F.A. Shepherd, S. Laurie, I. Gauthier, N. Leighl, E. Chen, R. Feld, J. Powers and L. Seymour	782

Internal mammary sentinel nodes: Ignore, irradiate or operate? N.J. Coombs, J. Boyages, J.R. French and O.A. Ung	789
Effectiveness of immediate preoperative injection of radiopharmaceutical and blue dye for sentinel node biopsy in patients with breast cancer J.M. Dixon, C. Mak, S. Radhakrishna, T. Kehoe, A.M. Millar, D. Wong and J.St.J. Thomas	795
Improving the efficiency of a chemotherapy day unit: Applying a business approach to oncology W.A.M. van Lent, N. Goedbloed and W.H. van Harten	800
Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study A. Gunnlaugsson, H. Anderson, E. Fernebro, E. Kjellén, P. Byström, Å. Berglund, M. Ekelund, L. Pählman, T. Holm, B. Glimelius and A. Johnsson	807
Paediatric oncology	
Testicular function of survivors of childhood cancer: A comparative study between ifosfamide- and cyclophosphamide-based regimens V. Ridola, O. Fawaz, F. Aubier, C. Bergeron, F. de Vathaire, F. Pichon, D. Orbach, J.C. Gentet, C. Schmitt, C. Dufour and O. Oberlin	814
Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: A Children's Cancer and Leukaemia Group (CCLG) study B. Messahel, R. Williams, A. Ridolfi, R. A'Hern, W. Warren, L. Tinworth, R. Hobson, R. Al-Saadi, G. Whyman, M.-A. Brundler, A. Kelsey, N. Sebire, C. Jones, G. Vujanic and K. Pritchard-Jones, On behalf of the Children's Cancer and Leukaemia Group (CCLG)	819
Epidemiology and cancer prevention	
The launch of Cancer Research UK's 'Reduce the Risk' campaign: Baseline measurements of public awareness of cancer risk factors in 2004 C. Redeker, J. Wardle, D. Wilder, S. Hiom and A. Miles	827
Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? A. Jakubowska, K. Jaworska, C. Cybulski, A. Janicka, J. Szymańska-Pasternak, M. Lener, S.A. Narod and J. Lubiński, the IHCC-Breast Cancer Study Group	837
Wine, liquor, beer and risk of breast cancer in a large population Y. Li, D. Baer, G.D. Friedman, N. Udaltsova, V. Shim and A.L. Klatsky	843
Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age H.P. van de Nieuwenhof, L.F.A.G. Massuger, I.A.M. van der Avoort, R.L.M. Bekkers, M. Casparie, W. Abma, L.C.L.T. van Kempen and J.A. de Hullu	851
Experimental oncology	
Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor D. Kong, M. Okamura, H. Yoshimi and T. Yamori	857
Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: A mechanism of lymphangiogenesis in lung cancer J. Ming, Q. Zhang, X. Qiu and E. Wang	866
Wilms' tumour gene 1 (WT1) as a target in curcumin treatment of pancreatic cancer cells W. Glienke, L. Maute, J. Wicht and L. Bergmann	874
Molecular prediction of early recurrence after resection of hepatocellular carcinoma S. Yoshioka, I. Takemasa, H. Nagano, N. Kittaka, T. Noda, H. Wada, S. Kobayashi, S. Marubashi, Y. Takeda, K. Umeshita, K. Dono, K. Matsubara and M. Monden	881

Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil	890
R. Ravizza, R. Molteni, M.B. Gariboldi, E. Marras, G. Perletti and E. Monti	

Corrigendum

Corrigendum to 'Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer' [EJC Supplement 6 (10) (2008) 3–11]	899
M.S. Aapro and G. von Minckwitz	

NUMBER 6

Survival of Cancer Patients in Europe, 1995–2002: The EUROCARE 4 Study **Guest Editors: R. Capocaccia, A. Gavin, T. Hakulinen, J.-M. Lutz and M. Sant**

Editorial comment

Comparative cancer survival information in Europe	901
F. Berrino, A. Verdecchia, J.M. Lutz, C. Lombardo, A. Micheli and R. Capocaccia, the EUROCARE Working Group	
The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis	909
R. De Angelis, S. Francisci, P. Baili, F. Marchesi, P. Roazzi, A. Belot, E. Crocetti, P. Pury, A. Knijn, M. Coleman and R. Capocaccia, the EUROCARE Working Group	
EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary	931
M. Sant, C. Allemani, M. Santaquilani, A. Knijn, F. Marchesi and R. Capocaccia, the EUROCARE Working Group	
Survival of European children and young adults with cancer diagnosed 1995–2002	992
G. Gatta, G. Zigon, R. Capocaccia, J.W. Coebergh, E. Desandes, P. Kaatsch, G. Pastore, R. Peris-Bonet and C.A. Stiller, the EUROCARE Working Group	
The cancer survival gap between elderly and middle-aged patients in Europe is widening	1006
A. Quaglia, A. Tavilla, L. Shack, H. Brenner, M. Janssen-Heijnen, C. Allemani, M. Colonna, E. Grande, P. Grosclaude and M. Vercelli, the EUROCARE Working Group	
The advantage of women in cancer survival: An analysis of EUROCARE-4 data	1017
A. Micheli, R. Ciampichini, W. Oberaigner, L. Ciccolallo, E. de Vries, I. Izarzugaza, P. Zambon, G. Gatta and R. De Angelis, the EUROCARE Working Group	
Long-term survival expectations of cancer patients in Europe in 2000–2002	1028
H. Brenner, S. Francisci, R. de Angelis, R. Marcos-Gragera, A. Verdecchia, G. Gatta, C. Allemani, L. Ciccolallo, M. Coleman and M. Sant, the EUROCARE Working Group	
Survival trends in European cancer patients diagnosed from 1988 to 1999	1042
A. Verdecchia, S. Guzzinati, S. Francisci, R. De Angelis, F. Bray, C. Allemani, A. Tavilla, M. Santaquilani and M. Sant, the EUROCARE Working Group	
The cure of cancer: A European perspective	1067
S. Francisci, R. Capocaccia, E. Grande, M. Santaquilani, A. Simonetti, C. Allemani, G. Gatta, M. Sant, G. Zigon, F. Bray and M. Janssen-Heijnen, the EUROCARE Working Group	
Multiple tumours in survival estimates	1080
S. Rosso, R. De Angelis, L. Ciccolallo, E. Carrani, I. Soerjomataram, E. Grande, G. Zigon and H. Brenner, the EUROCARE Working Group	

NUMBER 7

News	1095
Editorial comments	
Being NICE is not the problem! B. Jonsson	1100
Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS) A. Gronchi, I. Judson, T. Nishida, A. Poveda, J. Martin, P. Reichardt, P.G. Casali, A.L. Cesne, P. Hohenberger and J.-Y. Blay	1103
Short communication	
Endoscopic microwave coagulation therapy for early recurrent T1 nasopharyngeal carcinoma H.-Q. Mai, H.-Y. Mo, J.-F. Deng, M.-Q. Deng, W.-Y. Mai, X.-M. Huang, X. Guo and M.-H. Hong	1107
Current perspective	
TNM: Therapeutically Not Mandatory R.J. Epstein	1111
Reviews	
Resistance to EGF-R (erbB-1) and VEGF-R modulating agents W.C.M. Dempke and V. Heinemann	1117
The promises and pitfalls of epigenetic therapies in solid tumours J.S. Graham, S.B. Kaye and R. Brown	1129
Epigenetic therapies in haematological malignancies: Searching for true targets L. Altucci and S. Minucci	1137
Clinical oncology	
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: The EORTC QLQ-BM22 E. Chow, A. Hird, G. Velikova, C. Johnson, L. Dewolf, A. Bezjak, J. Wu, J. Shafiq, O. Sezer, D. Kardamakis, Y. van der Linden, B. Ma, M. Castro, P.F. Arnalot, S. Ahmedzai, M. Clemons, P. Hoskin, A. Yee, M. Brundage and A. Bottomley, on behalf of the EORTC Quality of Life Group	1146
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer C. Sessa, A. Perotti, C. Noberasco, F. De Braud, E. Gallerani, S. Cresta, M. Zucchetti, L. Viganò, A. Locatelli, J. Jimeno, J.W. Feilchenfeldt, M. D'Incalci, G. Capri, N. Ielmini and L. Gianni	1153
Screen-detected breast lesions with malignant needle core biopsy diagnoses and no malignancy identified in subsequent surgical excision specimens (potential false-positive diagnosis) E.A. Rakha, M.E. El-Sayed, J. Reed, A.H.S. Lee, A.J. Evans and I.O. Ellis	1162
Obtaining 'fresh' consent for genetic research with biological samples archived 10 years ago E. Vermeulen, M.K. Schmidt, N.K. Aaronson, M. Kuenen and F.E. van Leeuwen	1168
The abdominoperineal resection itself is associated with an adverse outcome: The European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer M. den Dulk, H. Putter, L. Collette, C.A.M. Marijnen, J. Folkesson, J.-F. Bosset, C. Rödel, K. Bujko, L. Pahlman and C.J.H. van de Velde	1175

Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy K. Jordan, I. Kinitz, W. Voigt, T. Behlendorf, H.-H. Wolf and H.-J. Schmoll	1184
Public funding of new cancer drugs: Is NICE getting nastier? A.R. Mason and M.F. Drummond	1188
Long-term morbidity of adjuvant whole abdominal radiotherapy (WART) or chemotherapy for early stage ovarian cancer M.J.A. Engelen, B.J. Snel, M. Schaapveld, E. Pras, E.G.E. de Vries, J.A. Gietema, A.G.J. van der Zee and P.H.B. Willemse	1193
Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial S. Mook, H. Bonnefoi, G. Pruneri, D. Larsimont, J. Jaskiewicz, M.D. Sabadell, G. MacGrogan, L.J. van't Veer, F. Cardoso and E.J. Rutgers	1201
Paediatric oncology	
Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91 K. von Hoff, B. Hinkes, N.U. Gerber, F. Deinlein, U. Mittler, C. Urban, M. Benesch, M. Warmuth-Metz, N. Soerensen, I. Zwiener, H. Goette, P.G. Schlegel, T. Pietsch, R.D. Kortmann, J. Kuehl and S. Rutkowski	1209
Epidemiology and cancer prevention	
Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timeliness I.K. Larsen, M. Småstuen, T.B. Johannesen, F. Langmark, D.M. Parkin, F. Bray and B. Møller	1218
Overweight, obesity and risk of haematological malignancies: A cohort study of Swedish and Finnish twins K.C. Söderberg, J. Kaprio, P.K. Verkasalo, E. Pukkala, M. Koskenvuo, E. Lundqvist and M. Feychting	1232
Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population R. Li, Y.Y. Shugart, W. Zhou, Y. An, Y. Yang, Y. Zhou, B. Zhang, D. Lu, H. Wang, J. Qian and L. Jin	1239
The impact of socioeconomic factors on 30-day mortality following elective colorectal cancer surgery: A nationwide study B.L. Frederiksen, M. Osler, H. Harling on behalf of Danish Colorectal Cancer Group, S. Ladelund and T. Jørgensen	1248
Experimental oncology	
β -Carotene promotes the development of NNK-induced small airway-derived lung adenocarcinoma H.A.N. Al-Wadei and H.M. Schuller	1257
Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway D.D. Meira, I. Nóbrega, V.H. de Almeida, J.S. Mororó, A.M. Cardoso, R.L.A. Silva, R.M. Albano and C.G. Ferreira	1265
Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy S. Chuthapisith, B.E. Bean, G. Cowley, J.M. Eremin, S. Samphao, R. Layfield, I.D. Kerr, J. Wiseman, M. El-Sheemy, T. Sreenivasan and O. Eremin	1274
Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma C.D. Jee, M.A. Kim, E.J. Jung, J. Kim and W.H. Kim	1282
Down-regulation of K-ras and H-ras in human brain gliomas R. Lymbouridou, G. Soufla, A.M. Chatzinikola, A. Vakis and D.A. Spandidos	1294
Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: Analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases I. Mylonas, S. Worbs, N. Shabani, C. Kuhn, S. Kunze, S. Schulze, D. Dian, A. Ginkelmaier, C. Schindlbeck, A. Brüning, H. Sommer, U. Jeschke and K. Friesse	1304

Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein L. Humpolíkova-Adámková, J. Kovařík, L. Dušek, L. Lauferová, V. Boudný, V. Fait, M. Fojtová, E. Krejčí and A. Kovařík	1315
---	------

Calendar of Forthcoming Meetings	I
---	----------

NUMBER 8

News	1325
-------------	------

Editorial

Positioning pemetrexed in the treatment of ovarian cancer J.A. Ledermann and J. Stebbing	1330
---	------

Reviews

C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation E. De Mattia and G. Toffoli	1333
--	------

Nitric oxide delivery to cancer: Why and how? P. Sonveaux, B.F. Jordan, B. Gallez and O. Feron	1352
---	------

A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: A critical appraisal W.H. Oldenmenger, P.A.E. Sillevs Smitt, S. van Dooren, G. Stoter and C.C.D. van der Rijt	1370
--	------

Clinical oncology

Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases U. Veronesi, V. Galimberti, G. Paganelli, P. Maisonneuve, G. Viale, R. Orecchia, A. Luini, M. Intra, P. Veronesi, P. Caldarella, G. Renne, N. Rotmensz, C. Sangalli, L. De Brito Lima, M. Tullii and S. Zurrida	1381
--	------

Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: A systematic review and meta-analysis P. Gu, Y.-Z. Zhao, L.-Y. Jiang, W. Zhang, Y. Xin and B.-H. Han	1389
--	------

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation K.J. Dedes, K. Matter-Walstra, M. Schwenkglenks, B.C. Pestalozzi, D. Fink, P. Brauchli and T.D. Szucs	1397
---	------

Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: Correlation with clinical parameters and outcome R. Mouawad, J.-P. Spano, E. Comperat, F. Capron and D. Khayat	1407
---	------

A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer I. Vergote, H. Calvert, M. Kania, C. Kaiser, A.H. Zimmermann and J. Sehouli	1415
--	------

Improving the efficacy of cancer immunotherapy J. Copier, A.G. Dalglish, C.M. Britten, L.H. Finke, G. Gaudernack, S. Gnjjatic, K. Kallen, R. Kiessling, M. Schuessler-Lenz, H. Singh, J. Talmadge, H. Zwierzina and L. Håkansson	1424
---	------

Paediatric oncology

Evaluation of alternative prognostic stratifications by prediction accuracy measures on individual survival with application to childhood leukaemia P. De Lorenzo, L. Antolini and M.G. Valsecchi	1432
--	------

Epidemiology and cancer prevention

- Glutathione S-transferase P1 gene polymorphism associated with gastric cancer among Caucasians 1438
Y. Zhou, N. Li, W. Zhuang, Y.-q. Yin, G.-J. Liu, T.-X. Wu, X. Yao, L. Du, M.-L. Wei and X.-T. Wu

- MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls 1443

J.-L. Bai, M.-H. Zheng, X. Xia, M. Ter-Minassian, Y.-P. Chen and F. Chen

- Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland 1450
L. Sharp, A.-E. Carsin, D.P. Cronin-Fenton, D. O'Driscoll and H. Comber

- Prevalence of patients with colorectal cancer requiring follow-up or active treatment 1460
M. Chauvenet, C. Lepage, V. Jooste, V. Cottet, J. Faivre and A.-M. Bouvier

Experimental oncology

- Cdc2 as prognostic marker in stage UICC II colon carcinomas 1466
A. Meyer, S. Merkel, W. Brückl, V. Schellerer, C. Schildberg, V. Campean, W. Hohenberger and R.S. Croner

- Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent 1474
G. Lorusso, N. Vannini, I. Sogno, L. Generoso, S. Garbisa, D.M. Noonan and A. Albini

- A new strategy to screen MMR genes in Lynch Syndrome: HA-CAE, MLPA and RT-PCR 1485
L. Perez-Cabornero, E. Velasco, M. Infante, D. Sanz, E. Lastra, L. Hernández, C. Miner and M. Duran

- Immune modulation and apoptosis induction: Two sides of antitumoural activity of a standardised herbal formulation of *Withania somnifera* 1494

F. Malik, A. Kumar, S. Bhushan, D.M. Mondhe, H.C. Pal, R. Sharma, A. Khajuria, S. Singh, G. Singh, A.K. Saxena, K.A. Suri, G.N. Qazi and J. Singh

- The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer 1510
D.J. Brennan, S. Ek, E. Doyle, T. Drew, M. Foley, G. Flannelly, D.P. O'Connor, W.M. Gallagher, S. Kilpinen, O.-P. Kallioniemi, K. Jirstrom, C. O'Herlihy and C.A.K. Borrebaeck

- A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib 1518

M.J. Donovan, A. Kotsianti, V. Bayer-Zubek, D. Verbel, M. Teverovskiy, C. Cordon-Cardo, J. Costa, F.A. Greco, J.D. Hainsworth and D.V. Parums

- Calendar of Forthcoming Meetings** I

NUMBER 9

- News** 1527

Short communication

- A Prime minister managed to attract elderly men in a Belgian Euromelanoma campaign 1532
V. del Marmol, E. de Vries, D. Roseeuw, C. Pirard, J. van der Endt, M. Trakatelli and T. Maselis

Current perspective

- Will children with cancer benefit from the new European Paediatric Medicines Regulation? 1535
G. Vassal

Reviews

- Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy – A technique in its infancy but already successful in fertility preservation 1547

M. von Wolff, J. Donnez, O. Hovatta, V. Keros, T. Maltaris, M. Montag, B. Salle, M. Sonmezer and C.Y. Andersen

A literature review of assumptions on test characteristics and adherence in economic evaluations of colonoscopy and CT-colonography screening P. van Gils, M. van den Berg, H. van Kranen and A.G. de Wit	1554
Late morbidity associated with a tumour-negative sentinel lymph node biopsy in primary breast cancer patients: A systematic review C.-q. Liu, Y. Guo, J.-y. Shi and Y. Sheng	1560
Clinical oncology	
Towards more patient centred healthcare: A new Consumer Quality Index instrument to assess patients' experiences with breast care O.C. Damman, M. Hendriks and H.J. Sixma	1569
Risk factors for sexual dysfunction after rectal cancer treatment M.M. Lange, C.A.M. Marijnen, C.P. Maas, H. Putter, H.J. Rutten, A.M. Stiggelbout, E.M.-K. Kranenbarg and C.J.H. van de Velde, Cooperative clinical investigators of the Dutch. Total mesorectal excision trial	1578
A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine T.E. Ciuleanu, A.V. Pavlovsky, G. Bodoky, A.M. Garin, V.K. Langmuir, S. Kroll and G.T. Tidmarsh	1589
The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies B. Lee, I. Franklin, J.S. Lewis, R.C. Coombes, R. Leonard, P. Gishen and J. Stebbing	1597
Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study H. Ludwig, M. Aapro, C. Bokemeyer, K. MacDonald, P. Soubeyran, M. Turner, T. Albrecht and I. Abraham	1603
Paediatric oncology	
Follow-up care after childhood cancer: Survivors' expectations and preferences for care G. Michel, D.M. Greenfield, K. Absolom, R.J. Ross, H. Davies and C. Eiser, On behalf of the Late Effects Group Sheffield	1616
Epidemiology and cancer prevention	
Geographical analysis of thyroid cancer in young people from northern England: Evidence for a sustained excess in females in Cumbria B.L. Magnanti, M. Tevfik Dorak, L. Parker, A.W. Craft, P.W. James and R.J.Q. McNally	1624
Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method – Analysis of 2010 Taiwanese patients C.-H. Chen, F.-C. Hu, G.-T. Huang, P.-H. Lee, Y.-M. Tsang, A.-L. Cheng, D.-S. Chen, J.-D. Wang and J.-C. Sheu	1630
Maternal smoking during pregnancy and testicular cancer in the sons: A nested case-control study and a meta-analysis J. Tuomisto, K. Holl, P. Rantakokko, P. Koskela, G. Hallmans, G. Wadell, P. Stattin, J. Dillner, H.M. Ögmundsdottir, T. Vartiainen, M. Lehtinen and E. Pukkala	1640
Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? D.M. Parkin	1649
Experimental oncology	
Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas R.J. Cuthbert, J.M. Wilson, N. Scott, P.L. Coletta and M.A. Hull	1654
Prostate cancer lesions are surrounded by FOXP3 ⁺ , PD-1 ⁺ and B7-H1 ⁺ lymphocyte clusters K. Ebel, G. Babaryka, B. Frankenberger, C.G. Stief, W. Eisenmenger, T. Kirchner, D.J. Schendel and E. Noessner	1664

Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer C. Parr and W.G. Jiang	1673
Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines J.E. Nutt, K. O'Toole, D. Gonzalez and J. Lunec	1684
Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML M. Terwijn, N. Feller, A. van Rhenen, A. Kelder, G. Westra, S. Zweegman, G. Ossenkoppele and G.J. Schuurhuis	1692
EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma M. Ryott, D. Wangsa, K. Heselmeyer-Haddad, J. Lindholm, G. Elmberger, G. Auer, E.Å. Lundqvist, T. Ried and E. Munck-Wikland	1700
Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells T.X. Lee, M.D. Packer, J. Huang, E.M. Akhmametyeva, S.K. Kulp, C.-S. Chen, M. Giovannini, A. Jacob, D.B. Welling and L.-S. Chang	1709
Calendar of Forthcoming Meetings	I

NUMBER 10

News	1721
Editorial	
How, and when, to say no A.R. Kagan	1726
Short communication	
Local control of the primary tumour in metastatic neuroblastoma I. Sultan, K. Ghandour, U. Al-Jumaily, S. Hashem and C. Rodriguez-Galindo	1728
Current perspective	
Predictive signatures for chemotherapy sensitivity in breast cancer: Are they ready for use in the clinic? H. Bonnefoi, C. Underhill, R. Iggo and D. Cameron	1733
Reviews	
Assessment of health-related quality of life after bone cancer in young people: Easier said than done C. Eiser	1744
A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases A. Stang, R. Fischbach, W. Teichmann, C. Bokemeyer and D. Braumann	1748
Clinical oncology	
Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX K. Shitara, K. Matsuo, D. Takahari, T. Yokota, Y. Inaba, H. Yamaura, Y. Sato, M. Najima, T. Ura and K. Muro	1757
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours J.J.E.M. Kitzen, M.J.A. de Jonge, C.H.J. Lamers, F.A.L.M. Eskens, D. van der Biessen, L. van Doorn, J. ter Steeg, M. Brandely, Ch. Puzozzo and J. Verweij	1764
The use of PTC and RFA as treatment alternatives with low procedural morbidity in non-small cell lung cancer Y.H. Choe, S.R. Kim, K.S. Lee, K.Y. Lee, S.J. Park, G.Y. Jin and Y.C. Lee	1773

The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast E.A. Rakha, M. Aleskandarany, M.E. El-Sayed, R.W. Blamey, C.W. Elston, I.O. Ellis and A.H.S. Lee	1780
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study J.-C. Barbare, O. Bouché, F. Bonnetain, L. Dahan, C. Lombard-Bohas, R. Faroux, J.-L. Raoul, S. Cattin, A. Lemoine, J.-F. Blanc, J.-P. Bronowicki, J.-P. Zarski, S. Cazorla, D. Gargot, T. Thevenot, E. Diaz, A. Bastie, T. Aparicio and L. Bedenne	1788
Enhancing the capacity of oncology nurses to provide supportive care for parents with advanced cancer: Evaluation of an educational intervention J. Turner, A. Clavarino, P. Butow, P. Yates, M. Hargraves, V. Connors and S. Hausmann	1798
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951) S.S. Agarwala, U. Keilholz, E. Gilles, A.Y. Bedikian, J. Wu, R. Kay, C.A. Stein, L.M. Itri, S. Suciu and A.M.M. Eggermont	1807
Paediatric oncology	
Relapsed intracranial ependymoma in children in the UK: Patterns of relapse, survival and therapeutic outcome B. Messahel, S. Ashley, F. Saran, D. Ellison, J. Ironside, K. Phipps, T. Cox, W.K. Chong, K. Robinson, S. Picton, C.R. Pinkerton, C. Mallucci, D. Macarthur, T. Jaspan, A. Michalski and R.G. Grundy, On behalf of the Children's Cancer Leukaemia Group Brain Tumour Committee	1815
Epidemiology and cancer prevention	
Genetic variation in sodium-dependent ascorbic acid transporters and risk of gastric cancer in Poland M.E. Wright, G. Andreotti, J. Lissowska, M. Yeager, W. Zatonski, S.J. Chanock, W.-H. Chow and L. Hou	1824
Metabolic syndrome and risk of cancer mortality in men J.R. Jaggers, X. Sui, S.P. Hooker, M.J. LaMonte, C.E. Matthews, G.A. Hand and S.N. Blair	1831
Unrelieved symptoms of female cancer patients during their last months of life and long-term psychological morbidity in their widowers: A nationwide population-based study J.M. Jonasson, A. Hauksdóttir, U. Valdimarsdóttir, C.J. Fürst, E. Onelöv and G. Steineck	1839
Experimental oncology	
Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors T. Liu, P.Y. Liu, A.E.L. Tee, M. Haber, M.D. Norris, M.E. Gleave and G.M. Marshall	1846
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models Y.-H. Ling, M. Aracil, J. Jimeno, R. Perez-Soler and Y. Zou	1855
Germline variations of the MALT1 gene as risk factors in the development of primary gastric B-cell lymphoma S. Hellmig, T. Bartscht, W. Fischbach, S.J. Ott, P. Rosenstiel, W. Klapper, U.R. Fölsch and S. Schreiber	1865
E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer M. Hebbar, A. Adenis, F. Révillion, A. Duhamel, O. Romano, S. Truant, C. Libersa, C. Giraud, J.-P. Triboulet, F.-R. Pruvot and J.-P. Peyrat	1871
Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia E. San José-Eneriz, X. Agirre, A. Jiménez-Velasco, L. Cordeu, V. Martín, V. Arqueros, L. Gárate, V. Fresquet, F. Cervantes, J.A. Martínez-Clement, A. Heiniger, A. Torres, F. Prósper and J. Roman-Gomez	1877
Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis G. Des Guetz, O. Schischmanoff, P. Nicolas, G.-Y. Perret, J.-F. Morere and B. Uzzan	1890
Calendar of Forthcoming Meetings	I

NUMBER 11

News	1897
Editorial comment	
Molecular markers of chemotherapy in advanced colorectal cancer: Back to square one <i>A. Sobrero</i>	1902
Short communication	
R(+)-XK469 inhibits hydroxylation of S-warfarin by CYP2C9 <i>W.P. Yong, T.W. Kim, S.D. Undevia, F. Innocenti and M.J. Ratain</i>	1904
Current perspective	
Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy? <i>R.E. Coleman</i>	1909
Reviews	
How effective are breast cancer screening programmes by mammography? Review of the current evidence <i>D. Schopper and C. de Wolf</i>	1916
Angiogenesis in pre-malignant conditions <i>M. Raica, A.M. Cimpean and D. Ribatti</i>	1924
A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? <i>M. Koopman, S. Venderbosch, I.D. Nagtegaal, J.H. van Krieken and C.J. Punt</i>	1935
Clinical oncology	
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03 <i>S. Teramukai, T. Kitano, Y. Kishida, M. Kawahara, K. Kubota, K. Komuta, K. Minato, T. Mio, Y. Fujita, T. Yonei, K. Nakano, M. Tsuboi, K. Shibata, K. Furuse and M. Fukushima</i>	1950
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure <i>S. George, J.Y. Blay, P.G. Casali, A. Le Cesne, P. Stephenson, S.E. DePrimo, C.S. Harmon, C.N.J. Law, J.A. Morgan, I. Ray-Coquard, V. Tassell, D.P. Cohen and G.D. Demetri</i>	1959
Hyperthermia dose-effect relationship in 420 patients with cervical cancer treated with combined radiotherapy and hyperthermia <i>M. Franckena, D. Fatehi, M. de Bruijne, R.A.M. Canters, Y. van Norden, J.W. Mens, G.C. van Rhoon and J. van der Zee</i>	1969
Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma <i>A. Vincent-Salomon, M. Caly, Y. De Rycke, P. Fréneaux, J. Klijanienko, M. Laé, F. Viard, C. Nos, F.-C. Bidard, S. Alran, R. Salmon, Y. Kirova, J.-Y. Pierga, B. Sigal-Zafrani and X. Sastre-Garau</i>	1979
Health care costs for treatment of disseminated breast cancer <i>L. Dahlberg, J. Lundkvist and H. Lindman</i>	1987
Developing a CTCAEs patient questionnaire for late toxicity after head and neck radiotherapy <i>K.F. Ho, D.J.J. Farnell, J.A. Routledge, M.P. Burns, A.J. Sykes, N.J. Slevin and S.E. Davidson</i>	1992
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study <i>M. Koopman, S. Venderbosch, H. van Tinteren, M.J. Ligtenberg, I. Nagtegaal, J.H. Van Krieken and C.J. Punt</i>	1999

Paediatric oncology

- Aggressive treatment of non-metastatic osteosarcoma improves health-related quality of life in children and adolescents 2007
P.S. Hinds, J.S. Gattuso, C.A. Billups, N.K. West, J. Wu, C. Rivera, J. Quintana, M. Villarroel and N.C. Daw

Epidemiology and cancer prevention

- MC1R variant alleles and malignant melanoma risk in Israel 2015
G. Galore-Haskel, E. Azizi, H. Mohamdi, A. Scope, V. Chaudru, Y. Laitman, F. Barak, F. Pavlotsky, F. Demenais and E. Friedman
- MDM2 309 T/G polymorphism is associated with lung cancer risk among Asians 2023
X.-H. Gui, L.-X. Qiu, H.-F. Zhang, D.-P. Zhang, W.-Z. Zhong, J. Li and Y.-L. Xiao
- Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: Estimates based on 1,875,708 screening colonoscopies 2027
H. Brenner, M. Hoffmeister, G. Brenner, L. Altenhofen and U. Haug

Experimental oncology

- CD133 and nuclear β -catenin: The marker combination to detect high risk cases of low stage colorectal cancer 2034
D. Horst, L. Kriegl, J. Engel, A. Jung and T. Kirchner
- The basal body gene, RPGRIP1L, is a candidate tumour suppressor gene in human hepatocellular carcinoma 2041
Y.-W. Lin, M.-D. Yan, Y.-L. Shih and C.-B. Hsieh
- The Ras inhibitor farnesylthiosalicylic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats 2050
T. Schneider-Merck, I. Borbath, N. Charette, C. De Saeger, J. Abarca, I. Leclercq, Y. Horsmans and P. Stärkel

Erratum

- Erratum to 'Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer – A study based on the EORTC trial 22881-10882 "boost versus no boost"' 2061

Calendar of Forthcoming Meetings I

NUMBER 12

News 2063

Editorial comment

- The capacity of the immune system to control cancer 2068
L. Håkansson

Current perspective

- Interplay between Numb and Notch in epithelial cancers: Role for dual oxidase maturation factor 2071
E.A. Ostrakhovitch

Reviews

- The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential 2077
L. Spencer, C. Mann, M. Metcalfe, M. Webb, C. Pollard, D. Spencer, D. Berry, W. Steward and A. Dennison
- Therapeutic vaccines in solid tumours: Can they be harmful? 2087
A.M.M. Eggermont

Clinical oncology

- Superficial soft tissue sarcomas (S-STs): A study of 367 patients from the French Sarcoma Group (FSG) database 2091
S. Salas, E. Stoeckle, F. Collin, B. Bui, P. Terrier, L. Guillou, M. Trassard, D. Ranchere-Vince, F. Gregoire and J.-M. Coindre

Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients S.-K. Kim, H.J. Choi, S.-Y. Park, H.-Y. Lee, S.-S. Seo, C.W. Yoo, D.C. Jung, S. Kang and K.-S. Cho	2103
Cost comparison study of two different follow-up protocols after surgery for oesophageal cancer S. Polinder, E.M.L. Verschuur, P.D. Siersema, E.J. Kuipers and E.W. Steyerberg	2110
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours C. Sessa, S. Cresta, C. Noberasco, G. Capri, E. Gallerani, F. De Braud, M. Zucchetti, M. D'Incalci, A. Locatelli, S. Marsoni, I. Corradino, C. Minoia, P. Zintl and L. Gianni	2116
Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer R. Nakamura, M. Sakakibara, T. Nagashima, T. Sangai, M. Arai, T. Fujimori, S. Takano, T. Shida, Y. Nakatani and M. Miyazaki	2123
Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer K. Tamura, I. Okamoto, T. Ozaki, T. Kashii, K. Takeda, M. Kobayashi, K. Matsui, T. Shibata, T. Kurata, K. Nakagawa and M. Fukuoka	2132
Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer C.S.D. Roxburgh, J.M. Salmond, P.G. Horgan, K.A. Oien and D.C. McMillan	2138
Peritoneal disease in breast cancer: A specific entity with an extremely poor prognosis M. Tuthill, R. Pell, R. Guilian, A. Lim, M. Gudi, K.B. Contractor, J.S. Lewis, R.C. Coombes and J. Stebbing	2146
Epidemiology and cancer prevention	
Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: Setting an evidence-based benchmark for the best-quality cancer care W. Ng, S. Jacob, G. Delaney and M. Barton	2150
Web-based resources for sun protection information – A French-language evaluation E. Mahé, S. Qattini, A. Beauchet and P. Saiag	2160
Trends in cancer mortality among migrants in England and Wales, 1979–2003 S. Harding, M. Rosato and A. Teyhan	2168
Health behaviours in older cancer survivors in the English Longitudinal Study of Ageing C. Grimmett, J. Wardle and A. Steptoe	2180
Experimental oncology	
Characterisation of gene expression profiles of yeast cells expressing BRCA1 missense variants L. Di Cecco, E. Melissari, V. Mariotti, C. Iofrida, A. Galli, L. Guidugli, G. Lombardi, M.A. Caligo, P. Iacopetti and S. Pellegrini	2187
Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation W.C.S. Cho, A.S.C. Chow and J.S.K. Au	2197
Frequent hypermethylation of RASSF1A tumour suppressor gene promoter and presence of Merkel cell polyomavirus in small cell lung cancer P. Helmbold, C. Lahtz, E. Herpel, P.A. Schnabel and R.H. Dammann	2207
Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II L. Lu, D. Katsaros, K. Shaverdashvili, B. Qian, Y. Wu, I.A.R. de la Longrais, M. Preti, G. Menato and H. Yu	2212
Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells H. Akhdar, P. Loyer, C. Rauch, A. Corlu, A. Guillozo and F. Morel	2219

Corrigendum

- Corrigendum to 'The CAP-CR study: Direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine' [European Journal of Cancer 44 (2008) 2615–2622]
S. Lopatriello, D. Amoroso, S. Donati, O. Alabiso, L. Forti, A. Fornasiero, A. Smergo, A. Lalli, C. Iacono, A. Lucenti, L. D'Alonzo and C. Negrini 2228

Calendar of Forthcoming Meetings

I

NUMBER 13**News**

2229

Editorial comments

- Palliative chemotherapy: Do we need yet another end-point? 2234
J.P. van Meerbeeck and P. Baas

- PDGFR inhibition in brain tumours – Oft expectation fails where most it promises 2236
E. Raymond

Short communication

- Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer 2239
K. Das, D.T. Leong, A. Gupta, L. Shen, T. Putti, G.S. Stein, A.J. van Wijnen and M. Salto-Tellez

Current perspective

- Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point? 2249
P. Ohorodnyk, E.A. Eisenhauer and C.M. Booth

Reviews

- Capecitabine and vinorelbine in metastatic breast cancer 2253
A. Chan and M. Verrill

- Immunotherapy for malignant melanoma – Tracing Ariadne's thread through the labyrinth 2266
J.M. Grange, B. Krone and J.L. Stanford

- Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The 'personalised' approach? 2274
H. Brauch and V.C. Jordan

Clinical oncology

- Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer 2284
M.E. Straver, E.J.Th. Rutgers, N.S. Russell, H.S.A. Oldenburg, S. Rodenhuis, J. Wesseling, A. Vincent and M.T.F.D.V. Peeters

- Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib 2293
M. Montemurro, P. Schöffski, P. Reichardt, H. Gelderblom, J. Schütte, J.T. Hartmann, R. von Moos, B. Seddon, H. Joensuu, C.M. Wendtner, E. Weber, V. Grünwald, A. Roth and S. Leyvraz

- Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study 2298
G.V. Scagliotti, K. Park, S. Patil, J. Rolski, T. Goksel, R. Martins, S.J.M. Gans, C. Visseren-Grul and P. Peterson

- A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: A combined analysis of 10 EORTC trials 2304
J. Francart, E. Vaes, S. Henrard, C. Legrand, P. Baas, R. Gaafar, J.P. van Meerbeeck, R. Sylvester and A. Robert

Combining 6-fluoro-[¹⁸ F]-dihydroxyphenylalanine and [¹⁸ F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients H.-B. Fiebrich, A.H. Brouwers, K.P. Koopmans and E.G.E. de Vries	2312
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma F. Thomas, P. Rochaix, M. White-Koning, I. Hennebelle, J. Sarini, A. Benlyazid, L. Malard, J.-L. Lefebvre, E. Chatelut and J.P. Delord	2316
Phase 3 randomised study of canfosfamide (Telcyta [®] , TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer I. Vergote, N. Finkler, J. del Campo, A. Lohr, J. Hunter, D. Matei, J. Kavanagh, J.B. Vermorken, L. Meng, M. Jones, G. Brown, S. Kaye and The ASSIST-1 Study Group	2324
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers J.C. Soria, C. Massard, N. Magné, Th. Bader, C.D. Mansfield, J.Y. Blay, B.N. Bui, A. Moussy, O. Hermine and J.P. Armand	2333
Paediatric oncology	
Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium B. Georger, B. Morland, A. Ndiaye, F. Doz, G. Kalifa, A. Geoffray, F. Pichon, D. Frappaz, E. Chatelut, P. Opolon, S. Hain, F. Boderet, J. Bosq, J.-F. Emile, M.L. Deley, R. Capdeville, G. Vassal and on behalf of the Innovative Therapies for Children with Cancer (ITCC) European Consortium	2342
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours S. Baruchel, J.R. Sharp, U. Bartels, J. Hukin, I. Odame, C. Portwine, D. Strother, C. Fryer, J. Halton, M.J. Egorin, R.M. Reis, O. Martinho, D. Stempak, C. Hawkins, J. Gammon and E. Bouffet	2352
Epidemiology and cancer prevention	
Cutaneous melanoma mortality starting to change: A study of trends in Northern Ireland A. Montella, A. Gavin, R. Middleton, P. Autier and M. Boniol	2360
Prognostic factors and outcomes for osteosarcoma: An international collaboration E.E. Pakos, A.D. Nearchou, R.J. Grimer, H.D. Koumoullis, A. Abudu, J.A.M. Bramer, L.M. Jeys, A. Franchi, G. Scoccianti, D. Campanacci, R. Capanna, J. Aparicio, M.-D. Tabone, G. Holzer, F. Abdolvahab, P. Funovics, M. Dominkus, I. Ilhan, S.G. Berrak, A. Patino-Garcia, L. Sierrasesumaga, M. San-Julian, M. Garraus, A.S. Petrilli, R.J.G. Filho, C.R.P.D. Macedo, M.T.d.S. Alves, S. Seiwert, R. Nagarajan, T.P. Cripe and J.P.A. Ioannidis	2367
Regulatory aspects of genetic research with residual human tissue: Effective and efficient data coding M.K. Schmidt, E. Vermeulen, R.A.E.M. Tollenaar, L.J.V. Veer and F.E. van Leeuwen	2376
Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer E. Jullumstrø, S. Lydersen, B. Møller, O. Dahl and Tom-H.-H. Edna	2383
Experimental oncology	
Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model V. Charasson, D. Hillaire-Buys, I. Solassol, A. Laurand-Quancard, F. Pinguet, V.L. Morvan and J. Robert	2391
Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids V. Lobjois, C. Frongia, S. Jozan, I. Truchet and A. Valette	2402
β -Catenin expression in uterine sarcomas and its relation to clinicopathological parameters W. Kildal, M. Pradhan, V.M. Abeler, G.B. Kristensen and H.E. Danielsen	2412

The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer C. Pinheiro, A. Longatto-Filho, K. Simões, C.E. Jacob, C.J.C. Bresciani, B. Zilberstein, I. Cecconello, V.A.F. Alves, F. Schmitt and F. Baltazar	2418
The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation D. Carlisi, M. Lauricella, A. D'Anneo, S. Emanuele, L. Angileri, P.D. Fazio, A. Santulli, R. Vento and G. Tesoriere	2425
Calendar of Forthcoming Meetings	I
NUMBER 14	
News	2439
Editorial comment	
Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer M. Schmitt and F.C.G.J. Sweep	2444
Short communication	
Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma P. Hundsdoerfer, M. Albrecht, U. Rühl, R. Fengler, A.E. Kulozik and G. Henze	2447
Current perspective	
Current perspective: Bevacizumab in colorectal cancer – A time for reappraisal? A. Okines and D. Cunningham	2452
Reviews	
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology G. Maschmeyer, T. Beinert, D. Buchheidt, O.A. Cornely, H. Einsele, W. Heinz, C.P. Heussel, C. Kahl, M. Kiehl, J. Lorenz, H. Hof and G. Mattiuzzi	2462
Targeted therapies in the treatment of advanced/metastatic NSCLC A.G. Pallis, L. Serfass, R. Dziadziuszko, J.P. van Meerbeeck, D. Fennell, D. Lacombe, J. Welch and C. Gridelli	2473
Clinical oncology	
Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: A phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5) M. Magnusson, P. Höglund, K. Johansson, C. Jönsson, F. Killander, P. Malmström, A. Weddig and E. Kjellén	2488
Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial S. Alkner, P.-O. Bendahl, M. Fernö, B. Nordenskjöld and L. Rydén on behalf of the South Swedish and South-East Swedish Breast Cancer Groups	2496
Estimation of an optimal chemotherapy utilisation rate for colon cancer: An evidence-based benchmark for cancer care S. Jacob, W. Ng, R. Asghari, G.P. Delaney and M.B. Barton	2503
Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases K. Harris, E. Chow, L. Zhang, G. Velikova, A. Bezjak, J. Wu, M. Barton, O. Sezer, R. Eek, J. Shafiq, A. Yee, M. Clemons, M. Brundage, P. Hoskin, Y. van der Linden, C.D. Johnson and A. Bottomley on behalf of the EORTC Quality of Life Group	2510
A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion J.M. van Riel, G.J. Peters, L.H. Mammatas, R.J. Honeywell, A.C. Laan, R. Ruyter, F.G. van den Berg, G. Giaccone and C.J. van Groenigen	2519

Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study G.L. Willemoe, P.B. Hertel, A. Bartels, M.-B. Jensen, E. Balslev, B.B. Rasmussen, H. Mouridsen, B. Ejlersen and N. Brüner	2528
Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database M. Mandalà, G.L. Imberti, D. Piazzalunga, M. Belfiglio, R. Labianca, M. Barberis, L. Marchesi, P. Poletti, L. Bonomi, L. Novellino, K. Di Biagio, A. Milesi, U. Guerra and C. Tondini	2537
Paediatric oncology	
Radiation-induced thyroid changes: A retrospective and a prospective view M. Massimino, L. Gandola, F. Mattavelli, N. Pizzi, E. Seregini, F. Pallotti, F. Spreafico, A. Marchianò, M. Terenziani, G. Cefalo, V. Biassoni, C. Meazza, G. Trecate and P. Collini	2546
Health and persistent functional late effects in adult survivors of childhood CNS tumours: A population-based cohort study K.K. Boman, E. Hovén, M. Anclair, B. Lannering and G. Gustafsson	2552
Epidemiology and cancer prevention	
Meta-analysis of genetic polymorphisms and gastric cancer risk: Variability in associations according to race M. Loh, K.X. Koh, B.H. Yeo, C.M. Song, K.S. Chia, F. Zhu, K.G. Yeoh, J. Hill, B. Iacopetta and R. Soong	2562
Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy? R.C. Macefield, J.A. Lane, C. Metcalfe, L. Down, D.E. Neal, F.C. Hamdy and J.L. Donovan	2569
FASLG polymorphism is associated with cancer risk Y. Liu, Q.-J. Wen, Y. Yin, X.-T. Lu, S.-H. Pu, H.-P. Tian, Y.-F. Lou, Y.-N. Tang, X. Jiang, G.-S. Lu and J. Zhang	2574
Experimental oncology	
CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival V. Mirisola, A. Zuccarino, B.E. Bachmeier, M.P. Sormani, J. Falter, A. Nerlich and U. Pfeffer	2579
Ethidium bromide as a vital probe of mitochondrial DNA in carcinoma cells A.M. Villa and S.M. Doglia	2588
TRAIL-R1 polymorphisms and cancer susceptibility: An evidence-based meta-analysis B. Chen, S. Liu, X.-L. Wang, W. Xu, Y. Li, W.-H. Zhao and J.-Q. Wu	2598
In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma F. Pellizzari Tregno, A. Sau, S. Pezzola, C. Geroni, C. Lapenta, M. Spada, G. Filomeni, E. Bonanno, G. Federici and A.M. Caccuri	2606
Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression C. Gabellini, D. Trisciuglio, M. Desideri, A. Candiloro, Y. Ragazzoni, A. Orlandi, G. Zupi and D. Del Bufalo	2618
Calendar of Forthcoming Meetings	I

NUMBER 15

Cervical Cancer Screening in the European Union**Guest Editors: G. Ronco and A. Anttila****Editorial Comment**

Cervical cancer screening in Europe – Changes over the last 9 years G. Ronco and A. Anttila	2629
--	------

HPV infection in Europe H. De Vuyst, G. Clifford, N. Li and S. Franceschi	2632
Trends of cervical cancer mortality in the member states of the European Union M. Arbyn, A.O. Raifu, E. Weiderpass, F. Bray and A. Anttila	2640
Cervical cancer screening policies and coverage in Europe A. Anttila, L. von Karsa, A. Aasmaa, M. Fender, J. Patnick, M. Rebolj, F. Nicula, L. Vass, Z. Valerianova, L. Voti, C. Sauvaaget and G. Ronco	2649
Process performance of cervical screening programmes in Europe G. Ronco, M. van Ballegooijen, N. Becker, A. Chil, M. Fender, P. Giubilato, J. Kurtinaitis, L. Lancucki, E. Lynge, A. Morais, M. O'Reilly, P. Sørensen, O. Suteu, M. Rebolj, P. Veerus, M.P. Žakelj and A. Anttila	2659
The challenges of organising cervical screening programmes in the 15 old member states of the European Union M. Arbyn, M. Rebolj, I.M.C.M. De Kok, M. Fender, N. Becker, M. O'Reilly and B. Andrae	2671
Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union F.A. Nicula, A. Anttila, L. Neamtiu, M.P. Žakelj, R. Tachezy, A. Chil, M. Grce and V. Kesić	2679
Description of the national situation of cervical cancer screening in the member states of the European Union A. Anttila, G. Ronco and Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE)	2685
The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey D. Lévy-Bruhl, V. Bousquet, L.A. King, D. O'Flanagan, S. Bacci, P.L. Lopalco, S. Salmaso and the country specific VENICE gate keepers and contact points	2709
What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination E. Lynge, A. Antilla, M. Arbyn, N. Segnan and G. Ronco	2714

NUMBER 16

News	2723
Editorial comment	
Anal cancer: One step forward – Two steps sideways! R. Glynn-Jones	2728
Short communication	
APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the Apc ^{Min} mouse model in vivo S. Sale, I.L. Fong, C. de Giovanni, L. Landuzzi, K. Brown, W.P. Steward and A.J. Gescher	2731
Current perspective	
Expert opinion in melanoma: The sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden A.C.J. van Akkooi, A. Spatz, A.M.M. Eggermont, M. Mihm and M.G. Cook	2736
Position paper	
The importance of early symptom recognition in the context of early detection and cancer survival J.J. Ott, A. Ullrich and A.B. Miller	2743

Reviews

- The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: A systematic review 2749
J. Jassem, C. Carroll, S.E. Ward, E. Simpson and D. Hind
- Targeting the WNT/ β -catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options 2759
I. Gehrke, R.K. Gandhirajan and K.-A. Kreuzer
- Contemporary pre-clinical development of anticancer agents – What are the optimal preclinical models? 2768
G. Damia and M. D'Incalci

Clinical oncology

- Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014) 2782
O. Matzinger, F. Roelofs, L. Mineur, S. Koswig, E.M. Van Der Steen-Banasik, P. Van Houtte, K. Haustermans, L. Radosevic-Jelic, R.P. Mueller, P. Maingon, L. Collette and J.F. Bosset, for the EORTC Radiation Oncology and Gastrointestinal Tract Cancer Groups
- Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases 2792
F. Heitz, P. Harter, H.-J. Lueck, A. Fissler-Eckhoff, F. Lorenz-Salehi, S. Scheil-Bertram, A. Traut and A. du Bois
- Causes of postoperative mortality after surgery for ovarian cancer 2799
C.G. Gerestein, R.A.M. Damhuis, M. de Vries, A. Reedijk, C.W. Burger and G.S. Kooi
- Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients 2804
J. Bellmunt, F. Macià, D. Malmusi, J.A. Llorente, J. Carles, J. Lloreta, P. Foro, A. Gelabert, J. Albanell and X. Castells
- Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: A prospective observational safety study 2810
L. Slobbe, L. van der Waal, L.R. Jongman, P.J. Lugtenburg and B.J.A. Rijnders
- Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma 2818
C.P. Raut, M.R. Nucci, Q. Wang, J. Manola, M.M. Bertagnoli, G.D. Demetri, J.A. Morgan, M.G. Muto, C.D.M. Fletcher and S. George
- Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991 2825
O. Matzinger, F. Duclos, A. van den Bergh, C. Carrie, S. Villà, P. Kitsios, P. Poortmans, S. Sundar, E.M. van der Steen-Banasik, A. Gulyban, L. Collette and M. Bolla, for the EORTC Radiation Oncology Group

Paediatric oncology

- Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry 2835
A. Garaventa, S. Parodi, B. De Bernardi, D. Dau, C. Manzitti, M. Conte, F. Casale, E. Viscardi, M. Bianchi, P. D'Angelo, G.A. Zanazzo, R. Luksch, C. Favre, A. Tamburini and R. Haupt
- Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting 2843
R. Dommett, J. Geary, S. Freeman, J. Hartley, M. Sharland, A. Davidson, R. Tulloh, M. Taj, S. Stoneham and J.C. Chisholm

Epidemiology and cancer prevention

- Are survival predictions reliable? Hospital volume versus standardisation of histopathologic reporting for accuracy of survival estimates after pancreatoduodenectomy for adenocarcinoma 2850
A. Westgaard, S. Larønningen, C. Mellem, T.J. Eide, O.P.F. Clausen, B. Møller and I.P. Gladhaug

Inverse association between a pro-inflammatory genetic profile and <i>Helicobacter pylori</i> seropositivity among patients with chronic atrophic gastritis: Enhanced elimination of the infection during disease progression? L. Gao, M.N. Weck, A. Nieters and H. Brenner	2860
Overweight, obesity and gastric cancer risk: Results from a meta-analysis of cohort studies P. Yang, Y. Zhou, B. Chen, H.-W. Wan, G.-Q. Jia, H.-L. Bai and X.-T. Wu	2867
Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk – A meta-analysis S. Wang, F. Wang, X. Shi, J. Dai, Y. Peng, X. Guo, X. Wang, H. Shen and Z. Hu	2874
Experimental oncology	
Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1 α involvement in CYP3A4 repression C. Legendre, T. Hori, P. Loyer, C. Aninat, S. Ishida, D. Glaise, C. Lucas-Clerc, K. Boudjema, C. Guguen-Guillouzo, A. Corlu and F. Morel	2882
Screening of anti-glioma effects induced by sigma-1 receptor ligands: Potential new use for old anti-psychiatric medicines V. Mégallizzi, C. Decaestecker, O. Debeir, S. Spiegl-Kreinecker, W. Berger, F. Lefranc, R.E. Kast and R. Kiss	2893
Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia I.J. Hoogsteen, J. Lok, H.A.M. Marres, R.P. Takes, P.F.J.W. Rijken, A.J. van der Kogel and J.H.A.M. Kaanders	2906
Systematic amino acid substitutions improved efficiency of GD ₂ -peptide mimotope vaccination against neuroblastoma M. Bleeke, S. Fest, N. Huebener, C. Landgraf, B. Schraven, G. Gaedicke, R. Volkmer and H.N. Lode	2915
Calendar of Forthcoming Meetings	I

NUMBER 17

News	2923
Editorial comment	
Management of aggressive fibromatosis: Can we unravel the maze of treatment options? S. Sleijfer	2928
Short communication	
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis A. Constantinidou, R.L. Jones, M. Scurr, O. Al-Muderis and I. Judson	2930
Current perspective	
Human papilloma virus in head and neck cancer: The need for a standardised assay to assess the full clinical importance B.J.M. Braakhuis, R.H. Brakenhoff, C.J.L.M. Meijer, P.J.F. Snijders and C.R. Leemans	2935
Reviews	
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer X.B. Pivot, R.K. Li, E.S. Thomas, H.-C. Chung, L.E. Fein, V.F. Chan, J. Jassem, F.H. de Mendoza, P. Mukhopadhyay and H.H. Roché	2940
Stereotactic body radiation therapy for liver metastases O. Dawood, A. Mahadevan and K.A. Goodman	2947
Are we there yet? The state of the evidence base for guidelines on breaking bad news to cancer patients C.L. Paul, T. Clinton-McHarg, R.W. Sanson-Fisher, H. Douglas and G. Webb	2960

Clinical oncology

- QUOTE^{chemo}: A patient-centred instrument to measure quality of communication preceding chemotherapy treatment through the patient's eyes 2967
 J.C.M. van Weert, J. Jansen, G.-J. de Bruijn, J. Noordman, S. van Dulmen and J.M. Bensing
- Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer 2977
 J. Dauplat, G. Chene, C. Pomel, M.M. Dauplat, G.L. Bouëdec, F. Mishellany, N. Lagarde, Y.J. Bignon, P. Jaffeux, B. Aublet-Cuvelier, P. Dechelotte, J.L. Pouly and F. Penault-Llorca
- What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta? 2984
 M. Aapro, A. Barnadas, R.C. Leonard, M. Marangolo, M. Untch, L. Ukarma, H.-U. Burger, A. Scherhag and B. Osterwalder
- Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy 2992
 R. Gertler, R. Rosenberg, T. Schuster and H. Friess
- The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer 3000
 W. Lu, M. Schaapveld, L. Jansen, E. Bagherzadegan, M.M. Sahinovic, P.C. Baas, L.M.H.C. Hanssen, H.C.J. van der Mijle, J.D. Brandenburg, T. Wiggers and G.H. De Bock
- Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis 3008
 V. Varadi, A. Brendle, A. Brandt, R. Johansson, K. Enquist, R. Henriksson, U. Svenson, B. Tavelin, G. Roos, K. Hemminki, P. Lenner and A. Försti
- Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer 3017
 R.N. Whistance, T. Conroy, W. Chie, A. Costantini, O. Sezer, M. Koller, C.D. Johnson, S.A. Pilkington, J. Arraras, E. Ben-Josef, A.M. Pullyblank, P. Fayers and J.M. Blazeby, on behalf of the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Group

Paediatric oncology

- Cardiac or cardiopulmonary transplantation in childhood cancer survivors: An increasing need? 3027
 G. Levitt, A. Anazodo, M. Burch and K. Bunch
- Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma 3035
 G. Bisogno, A. Ferrari, A. Prete, C. Messina, E. Basso, G. Cecchetto, P. Indolfi, G. Scarzello, P. D'Angelo, L.D. Sio, A.D. Cataldo and M. Carli

Epidemiology and cancer prevention

- Long-term meat intake and risk of breast cancer by oestrogen and progesterone receptor status in a cohort of Swedish women 3042
 S.C. Larsson, L. Bergkvist and A. Wolk
- Cancer diagnosis in first-degree relatives and non-small cell lung cancer risk: Results from a multi-centre case-control study in Europe 3047
 A. Cassidy, J. Balsan, A. Vesin, X. Wu, T. Liloglou, C. Brambilla, J.-F. Timsit and J.K. Field, EUELC Consortium
- Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant 3054
 S. Caini, S. Gandini, F. Sera, S. Raimondi, M.C. Fargnoli, M. Boniol and B.K. Armstrong
- The influence of menopausal hormone therapy on tumour characteristics and survival in endometrial cancer patients 3064
 C.C. Orgéas, P. Hall, S. Wedrén, P.W. Dickman and K. Czene

Experimental oncology

- Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma 3074
 J.J.C. Verhoeff, L.J.A. Stalpers, A. Claes, K.E. Hovinga, G.D. Musters, W. Peter Vandertop, D.J. Richel, W.P.J. Leenders and W.R. van Furth

Analysis of Ki-67 and Bcl-2 protein expression in normal colorectal mucosa of women with breast cancer E.C. Sousa-Júnior, A.P. Alencar and B.B. da Silva	3081
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications S.G. Gray, N. Al-Sarraf, A.-M. Baird, M.-C. Cathcart, E. McGovern and K.J. O'Byrne	3087
The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size G. Liu, S. Dou, M. Liang, X. Chen, M. Rusckowski and D.J. Hnatowich	3098
MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines M.K. Muniyappa, P. Dowling, M. Henry, P. Meleady, P. Doolan, P. Gammell, M. Clynes and N. Barron	3104

Calendar of Forthcoming Meetings

I

NUMBER 18

News	3119
Reviews	
Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: A systematic review C.H.M. van Deurzen, B.E.P.J. Vriens, V.C.G. Tjan-Heijnen, E. van der Wall, M. Albregts, R. van Hilligersberg, E.M. Monnikhof and P.J. van Diest	3124
Antiviral prophylaxis in haematological patients: Systematic review and meta-analysis D. Yahav, A. Gafter-Guili, E. Muchtar, K. Skalsky, G. Kariiv, M. Yeshurun, L. Leibovici and M. Paul	3131
The mystery of male dominance in oesophageal cancer and the potential protective role of oestrogen E. Chandanos and J. Lagergren	3149
Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran – A review F. Islami, F. Kamangar, D. Nasrollahzadeh, H. Møller, P. Boffetta and R. Malekzadeh	3156
Clinical oncology	
An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence D. Puliti, M. Zappa, G. Miccinesi, P. Falini, E. Crocetti and E. Paci	3166
Prevalence, socio-demographic and clinical predictors of post-diagnostic utilisation of different types of complementary and alternative medicine (CAM) in a nationwide cohort of Danish women treated for primary breast cancer C.G. Pedersen, S. Christensen, A.B. Jensen and R. Zachariae	3172
The FAMCARE-Patient scale: Measuring satisfaction with care of outpatients with advanced cancer C. Lo, D. Burman, S. Hales, N. Swami, G. Rodin and C. Zimmermann	3182
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study) A. Fusi, S. Collette, A. Busse, S. Suciu, A. Rietz, M. Santinami, W.H.J. Kruit, A. Testori, C.J.A. Punt, A.G. Dalglish, A. Spatz, A.M.M. Eggermont and U. Keilholz	3189
The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 study M. Rosendahl, J. Ahlgren, J. Andersen, J. Bergh, C. Blomquist, E. Lidbrink, H. Lindman, H. Mouridsen, K. Bjerre and M. Andersson	3198
The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer P. Hadji, M. Ziller, C. Maskow, U. Albert and M. Kalder	3205

Paediatric oncology

- Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors 3213
 R. Skinner, A. Parry, L. Price, M. Cole, A.W. Craft and A.D.J. Pearson
- Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry 3220
 A.R. Gigliotti, A. Di Cataldo, S. Sorrentino, S. Parodi, A. Rizzo, P. Buffa, C. Granata, A.R. Sementa, A.M. Fagnani, M. Provenzi, A. Prete, C. D'Ippolito, A. Clerico, A. Castellano, G.P. Tonini, M. Conte, A. Garaventa and B. De Bernardi

Epidemiology and cancer prevention

- Variants of the xeroderma pigmentosum variant gene (POLH) are associated with melanoma risk 3228
 J. Di Lucca, M. Guedj, J.-J. Lacapère, M.C. Fagnoli, A. Bourillon, P. Dieudé, N. Dupin, P. Wolkenstein, P. Aegerter, P. Saiag, V. Descamps, C. Lebbe, N. Basset-Seguín, K. Peris, B. Grandchamp and N. Soufir
- Wounds and survival in cancer patients 3237
 V. Maida, M. Ennis, C. Kuziemy and J. Corban
- Cancer mortality in long-term survivors of retinoblastoma 3245
 T. Marees, F.E. van Leeuwen, M.R. de Boer, S.M. Imhof, P.J. Ringens and A.C. Moll
- Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: A case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study 3254
 S.M. Collin, C. Metcalfe, J.L. Donovan, J. Athene Lane, M. Davis, D.E. Neal, F.C. Hamdy and R.M. Martin
- Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor 3262
 M.A. Price, R. Zachariae, P.N. Butow, A. deFazio, D. Chauhan, C.A. Espie, M. Friedlander and P.M. Webb, The Australian Ovarian Cancer Study Group, The Australian Ovarian Cancer Study – Quality of Life Study Investigators
- Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data 3271
 J.A. Randerson-Moor, J.C. Taylor, F. Elliott, Y.-M. Chang, S. Beswick, K. Kukalich, P. Affleck, S. Leake, S. Haynes, B. Karpavicius, J. Marsden, E. Gerry, L. Bale, C. Bertram, H. Field, J.H. Barth, I. dos Santos Silva, A. Swerdlow, P.A. Kanetsky, J.H. Barrett, D.T. Bishop and J.A.N. Bishop
- Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: A French population-based controlled study (Wintzenheim trial) 3282
 B. Denis, I. Gendre, F. Aman, F. Ribstein, P. Maurin and P. Perrin
- Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: A population-based study of 2299 patients 3291
 G. Lughezzani, C. Jeldres, H. Isbarn, M. Sun, S.F. Shariat, A. Alasker, D. Pharand, H. Widmer, P. Arjane, M. Graefen, F. Montorsi, P. Perrotte and P.I. Karakiewicz
- Correcting population-based survival for DCOs – Why a simple method works and when to avoid it 3298
 P. Silcocks and C.S. Thomson
- Glutathione S-transferase P1 Ile105Val polymorphism and colorectal cancer risk: A meta-analysis and HuGE review 3303
 Y. Gao, X. Pan, T. Su, Z. Mo, Y. Cao and F. Gao

Experimental oncology

- Aquaporin-4 contributes to the resolution of peritumoural brain oedema in human glioblastoma multiforme after combined chemotherapy and radiotherapy 3315
 B. Nico, D. Mangieri, R. Tamma, V. Longo, T. Annese, E. Crivellato, B. Pollo, E. Maderna, D. Ribatti and A. Salmaggi

CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma G. Stocker, K. Ott, N. Henningsen, K. Becker, A. Hapfelmeier, F. Lordick, S. Hois, S. Plaschke, H. Höfler and G. Keller	3326
Testing additivity of anticancer agents in pre-clinical studies: A PK/PD modelling approach M. Rocchetti, F. Del Bene, M. Germani, F. Fiorentini, I. Poggesi, E. Pesenti, P. Magni and G. De Nicolao	3336
<i>Calendar of Forthcoming Meetings</i>	I

SUPPLEMENT 1

The role of new cytotoxic agents for the treatment of metastatic breast cancer

SUPPLEMENT 2

Joint ECCO 15 – 34th ESMO
Multidisciplinary Congress

Abstract Book

SUPPLEMENT 3

Joint ECCO 15 – 34th ESMO
Multidisciplinary Congress

Presidential sessions

Late Breaking and
Best of ECCO 15 – ESMO 34 Abstracts
and Best of 2009 Abstracts

SUPPLEMENT 4

Abstracts of the
EORTC – NCI – ASCO Annual Meeting
on
'Molecular Markers in Cancer'

15 – 17 October 2009
Brussels, Belgium